SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Concept art for large layoffs showing a line of blocks a cliff
Layoffs
AC Immune Downsizes by 30%, Narrows Pipeline Focus
The reprioritization effort will help AC Immune extend its cash runway through the third quarter of 2027.
September 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Washington, D.C., USA- January 13, 2020: FDA Sign at its headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.
Regulatory
‘All Wrapper, No Gift’: FDA Releases New Rare Disease Approval Framework
While the new framework signals continued flexibility at the FDA regarding rare disease approvals, some analysts and advocates question what tangible impacts the new guidelines will have.
September 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Vaccines
Prasad Demands YouTube Remove Videos Where He Criticized COVID-19 Vaccines
YouTube has shut down a channel containing hundreds of videos of comments made by doctors and other influencers—including CBER Director Vinay Prasad, Health Secretary Robert F. Kennedy Jr. and NIH Director Jay Bhattacharya—during the pandemic. This comes as Prasad reveals further details about last week’s updated COVID-19 approvals.
September 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Sea wave. Hand drawn realistic vector illustration in oriental vintage ukiyo-e style.
RNA editing
Wave Crashes Despite Successful RNA Editing in AATD Study
Wave’s RNA editor resulted in protein levels that were “exceedingly close” to what investors were expecting, but nevertheless fell short of that bar, according to analysts at Truist Securities.
September 4, 2025
 · 
2 min read
 · 
Tristan Manalac
The concept of medical care for heart disease cardiac rhythm in the chart of tablets
Opinion
DMD Gene Therapy’s Inflection Point and the Case for Small Molecules
As AAV9 and CRISPR programs navigate safety, delivery and scalability hurdles, small molecules offer a deployable, scalable bridge, complementing genetic approaches and accelerating meaningful impact for patients with Duchenne muscular dystrophy.
September 4, 2025
 · 
6 min read
 · 
David Craig
President Donald Trump delivers remarks at the Department of Justice in Washington, D.C., Friday, March 14, 2025. (Official White House Photo by Joyce N. Boghosian)
Vaccines
Pfizer CEO Responds to Trump’s COVID Transparency Call Touting Vaccine Success
Albert Bourla heralded the president’s COVID-19 leadership and Operation Warp Speed initiative as a Nobel Prize–worthy achievement and said that Pfizer stands by the integrity of the data already shared.
September 3, 2025
 · 
2 min read
 · 
Annalee Armstrong
Vaccines
Prasad Signals Steeper Requirements for COVID-19 Vaccines
In a series of memos last week, Center for Biologics Evaluation and Research Director Vinay Prasad outlined the FDA’s thinking on the recent limited approvals for updated COVID-19 vaccines.
September 3, 2025
 · 
3 min read
 · 
Tristan Manalac
HHS Secretary Robert F Kennedy Jr standing wearing a gray suit with his arms crossed
CDC
RFK Jr. Blames US COVID Deaths on Chronic Disease, Announcing CDC Reorganization
In an opinion piece in the Wall Street Journal, Health Secretary Robert F. Kennedy Jr. said he will roll chronic disease programs into a new Administration for a Healthy America.
September 3, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Cairo, Egypt, October 31 2024: Novartis CO building in Egypt, Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland, manufactures the drugs
Cardiovascular disease
Novartis Doubles Down on Argo Pact With Fresh $5.2B Commitment
Novartis and Argo Biopharma go back to January 2024, when the pharma first bet up to $4.165 billion across two RNAi agreements targeting cardiovascular diseases.
September 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS